This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Nov 19, 2025
by Zacks Equity Research
Companies in The News Are: MDT,MGIC,AS,ESLT
Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.
BSX's Neuromodulation Prospect Looks Strong: What's Behind It?
by Moumi Mondal
Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.
Medtronic (MDT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs
by Zacks Equity Research
MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.
Medtronic (MDT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of +3.82% and +1.11%, respectively, for the quarter ended October 2025. Do the numbers hold clues to what lies ahead for the stock?
Top Analyst Reports for Oracle, Costco & Cisco
by Mark Vickery
New analyst reports spotlight Oracle's cloud momentum, strategic partnerships and expected fiscal 2026 sales growth.
The Oncology Institute, Inc. (TOI) Reports Q3 Loss, Beats Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -16.67% and +11.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Medtronic (MDT) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2025.
MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth
by Zacks Equity Research
Medtronic's Q2 results may see a lift from solid Cardiovascular momentum and strong Diabetes segment growth.